CooperCompanies Announces First Quarter 2024 Results
SAN RAMON, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) — CooperCompanies (Nasdaq: COO), a leading global medical device company, today announced […]
The RealReal Announces Fourth Quarter and Full Year 2023 Results
Q4 and FY 2023 Net Loss Improved Year-Over-Yearby $17 million and $28 million, respectivelyQ4 2023 Adjusted EBITDA of positive $1.4 […]
Montauk Renewables Schedules Full Year 2023 Conference Call for Thursday, March 14, 2024, at 5:00 p.m. ET
PITTSBURGH, Feb. 29, 2024 (GLOBE NEWSWIRE) — Montauk Renewables, Inc. (“Montauk” or “the Company”) (NASDAQ: MNTK), a renewable energy company […]
Certara Reports Fourth Quarter 2023 Financial Results
PRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) — Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its […]
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update
– First patient dosed in Phase 2 first-line trial in patients with RAS-mutated mCRC for new lead program with the […]
Triumph Financial Announces Dividend for 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock
DALLAS, Feb. 29, 2024 (GLOBE NEWSWIRE) — Triumph Financial, Inc. (the “Company”) (Nasdaq: TFIN) today announced that the Company’s Board […]
Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRC
– New clinical data from second-line randomized ONSEMBLE trial provides further evidence of the efficacy of onvansertib in combination with […]
Gulf Island Announces Fourth Quarter and Full Year 2023 Results Conference Call Date
THE WOODLANDS, Texas, Feb. 29, 2024 (GLOBE NEWSWIRE) — Gulf Island Fabrication, Inc. (“Gulf Island” or the “Company”) (NASDAQ: GIFI), […]
Seer Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Full Year 2024 Outlook
REDWOOD CITY, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) — Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a […]
GeoVax Reports 2023 Year-End Financial Results and Provides Business Update
Progress across the pipeline in multiple clinical trials, includingPhase 2 program of GEO-CM04S1, next-generation Covid-19 vaccine, andmulticenter Phase 1/2 study […]
